Suppr超能文献

“如果你愿意,你可以隐藏它,如果你愿意,你也可以让它被看到”:一项使用 Omnipod DASH® 系统的澳大利亚 1 型糖尿病成人生活体验的定性研究。

"You can hide it if you want to, you can let it be seen if you want to": A qualitative study of the lived experiences of Australian adults with type 1 diabetes using the Omnipod DASH® system.

机构信息

Cairnmillar Institute, Camberwell, Victoria, Australia.

Cairnmillar Institute, Camberwell, Victoria, Australia; Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.

出版信息

Diabetes Res Clin Pract. 2024 Feb;208:111123. doi: 10.1016/j.diabres.2024.111123. Epub 2024 Feb 2.

Abstract

AIMS

Understanding the lived experience of using a tubeless insulin pump and how this differs compared to usual care (tubed insulin pump therapy (IPT) vs multiple daily injections (MDI)).

METHODS

Interviews were conducted after 12-weeks of using the Omnipod DASH Insulin Management System (Insulet, Acton, MA) and analysed using thematic analysis.

RESULTS

Fifty-eight adults (35 female; mean age 42;SD 13 years; 35 previous MDI) were interviewed. Most (84 %) wanted to continue using the device. Experiences fit two themes: 1. Taking back control of my diabetes: many previous MDI users perceived improved glycaemic control, explained by more "nuanced" control, with some reporting positive effects during exercise and sleep. Many previous MDI and IPT users endorsed positive experiences in concealing or disclosing their diabetes to others. However, some previous MDI users reported negative psychosocial experiences due to feeling continuously "attached" to their diabetes. 2. Barriers and facilitators of device acceptability: both MDI and IPT users cited wearability, alarms and the financial cost impacted their choice to continue device use. IPT users reported positive wearability experiences.

CONCLUSIONS

The tubeless pump improved diabetes management perceptions for both MDI and tubed pump users. However, participants' prior glucose management affected perceptions of its advantages and disadvantages.

摘要

目的

了解使用无管胰岛素泵的真实体验,以及与常规治疗(有管胰岛素泵治疗(IPT)与多次皮下注射(MDI))相比的不同之处。

方法

在使用 Omnipod DASH 胰岛素管理系统(Insulet,马萨诸塞州阿克顿) 12 周后进行了访谈,并采用主题分析进行分析。

结果

共访谈了 58 名成年人(女性 35 名;平均年龄 42 岁;SD 13 岁;35 名既往 MDI)。大多数(84%)受访者希望继续使用该设备。体验符合两个主题:1. 夺回对糖尿病的控制:许多既往 MDI 用户认为血糖控制得到改善,这可归因于更“细致”的控制,有些报告称在运动和睡眠期间有积极影响。许多既往 MDI 和 IPT 用户对向他人隐瞒或披露其糖尿病的经历表示认可。然而,一些既往 MDI 用户报告称由于感觉持续“依附”于其糖尿病,存在负性心理社会体验。2. 设备可接受性的障碍和促进因素:MDI 和 IPT 用户都提到了可穿戴性、警报和经济成本对他们继续使用设备的选择产生了影响。IPT 用户报告了积极的可穿戴体验。

结论

无管泵改善了 MDI 和有管泵使用者的糖尿病管理认知。然而,参与者既往的血糖管理影响了他们对其优缺点的看法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验